 | • レポートコード：MRC23Q36217 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の非筋層浸潤性膀胱がん治療薬市場について調査・分析し、世界の非筋層浸潤性膀胱がん治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（膀胱内化学療法、膀胱内免疫療法）、用途別セグメント分析（病院、外来手術センター、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、F. Hoffmann-La Roche Ltd.、Bristol-Myers Squibb Company、AstraZeneca、Pfizer Inc.、GlaxoSmithKline plc.、Sanofi S.A.、Novartis AG、Eli Lilly and Company、Merck & Co.、Viventia Bio Inc.、Celgene Corporation、Spectrum Pharmaceuticals, Inc.、Herantis Pharma Plc.、Taris Biomedical LLC、Prometic Life Sciences Inc.、Telormediz S.A.、Heat Biologics、Altor BioScience、Ferring B.V.、Cold Genesys Inc.などが含まれています。世界の非筋層浸潤性膀胱がん治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、非筋層浸潤性膀胱がん治療薬市場規模を推定する際に考慮しました。本レポートは、非筋層浸潤性膀胱がん治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、非筋層浸潤性膀胱がん治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・非筋層浸潤性膀胱がん治療薬市場の概要 - 非筋層浸潤性膀胱がん治療薬のタイプ別セグメント - 世界の非筋層浸潤性膀胱がん治療薬市場規模：タイプ別分析（膀胱内化学療法、膀胱内免疫療法） - 非筋層浸潤性膀胱がん治療薬の用途別セグメント - 世界の非筋層浸潤性膀胱がん治療薬市場規模：用途別分析（病院、外来手術センター、その他） - 世界の非筋層浸潤性膀胱がん治療薬市場規模予測（2018年-2029年） ・非筋層浸潤性膀胱がん治療薬市場の成長トレンド - 非筋層浸潤性膀胱がん治療薬の地域別市場規模（2018年-2029年） - 非筋層浸潤性膀胱がん治療薬市場ダイナミクス - 非筋層浸潤性膀胱がん治療薬の業界動向 - 非筋層浸潤性膀胱がん治療薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：膀胱内化学療法、膀胱内免疫療法 - 世界の非筋層浸潤性膀胱がん治療薬のタイプ別市場規模（2018年-2023年） - 世界の非筋層浸潤性膀胱がん治療薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、外来手術センター、その他 - 世界の非筋層浸潤性膀胱がん治療薬の用途別市場規模（2018年-2023年） - 世界の非筋層浸潤性膀胱がん治療薬の用途別市場規模（2024年-2029年） ・非筋層浸潤性膀胱がん治療薬の地域別市場規模 - 北米の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年） - アメリカの非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年） - ヨーロッパの非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年） - アジア太平洋の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年） - 中国の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年） - 日本の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年） - 韓国の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年） - インドの非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年） - オーストラリアの非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年） - 中南米の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年） - 中東・アフリカの非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 F. Hoffmann-La Roche Ltd.、Bristol-Myers Squibb Company、AstraZeneca、Pfizer Inc.、GlaxoSmithKline plc.、Sanofi S.A.、Novartis AG、Eli Lilly and Company、Merck & Co.、Viventia Bio Inc.、Celgene Corporation、Spectrum Pharmaceuticals, Inc.、Herantis Pharma Plc.、Taris Biomedical LLC、Prometic Life Sciences Inc.、Telormediz S.A.、Heat Biologics、Altor BioScience、Ferring B.V.、Cold Genesys Inc. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Non-muscle Invasive Bladder Cancer Therapeutics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Non-muscle Invasive Bladder Cancer Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Non-muscle Invasive Bladder Cancer Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Non-muscle Invasive Bladder Cancer Therapeutics in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Non-muscle Invasive Bladder Cancer Therapeutics include F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Eli Lilly and Company and Merck & Co., etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Non-muscle Invasive Bladder Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-muscle Invasive Bladder Cancer Therapeutics.
The Non-muscle Invasive Bladder Cancer Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Non-muscle Invasive Bladder Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-muscle Invasive Bladder Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
AstraZeneca
Pfizer Inc.
GlaxoSmithKline plc.
Sanofi S.A.
Novartis AG
Eli Lilly and Company
Merck & Co.
Viventia Bio Inc.
Celgene Corporation
Spectrum Pharmaceuticals, Inc.
Herantis Pharma Plc.
Taris Biomedical LLC
Prometic Life Sciences Inc.
Telormediz S.A.
Heat Biologics
Altor BioScience
Ferring B.V.
Cold Genesys Inc.
Segment by Type
Intravesical Chemotherapy
Intravesical Immunotherapy
Segment by Application
Hospital
Ambulatory Surgery Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-muscle Invasive Bladder Cancer Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Intravesical Chemotherapy
1.2.3 Intravesical Immunotherapy
1.3 Market by Application
1.3.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Ambulatory Surgery Center
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Perspective (2018-2029)
2.2 Non-muscle Invasive Bladder Cancer Therapeutics Growth Trends by Region
2.2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Non-muscle Invasive Bladder Cancer Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Non-muscle Invasive Bladder Cancer Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Non-muscle Invasive Bladder Cancer Therapeutics Market Dynamics
2.3.1 Non-muscle Invasive Bladder Cancer Therapeutics Industry Trends
2.3.2 Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers
2.3.3 Non-muscle Invasive Bladder Cancer Therapeutics Market Challenges
2.3.4 Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-muscle Invasive Bladder Cancer Therapeutics Players by Revenue
3.1.1 Global Top Non-muscle Invasive Bladder Cancer Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-muscle Invasive Bladder Cancer Therapeutics Revenue
3.4 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-muscle Invasive Bladder Cancer Therapeutics Revenue in 2022
3.5 Non-muscle Invasive Bladder Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Non-muscle Invasive Bladder Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Non-muscle Invasive Bladder Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-muscle Invasive Bladder Cancer Therapeutics Breakdown Data by Type
4.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Forecasted Market Size by Type (2024-2029)
5 Non-muscle Invasive Bladder Cancer Therapeutics Breakdown Data by Application
5.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
6.2 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2018-2023)
6.4 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
7.2 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2018-2023)
7.4 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
9.2 Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 F. Hoffmann-La Roche Ltd. Company Detail
11.1.2 F. Hoffmann-La Roche Ltd. Business Overview
11.1.3 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.1.4 F. Hoffmann-La Roche Ltd. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.1.5 F. Hoffmann-La Roche Ltd. Recent Development
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Detail
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.2.4 Bristol-Myers Squibb Company Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.2.5 Bristol-Myers Squibb Company Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.3.4 AstraZeneca Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.3.5 AstraZeneca Recent Development
11.4 Pfizer Inc.
11.4.1 Pfizer Inc. Company Detail
11.4.2 Pfizer Inc. Business Overview
11.4.3 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.4.4 Pfizer Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.4.5 Pfizer Inc. Recent Development
11.5 GlaxoSmithKline plc.
11.5.1 GlaxoSmithKline plc. Company Detail
11.5.2 GlaxoSmithKline plc. Business Overview
11.5.3 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.5.4 GlaxoSmithKline plc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.5.5 GlaxoSmithKline plc. Recent Development
11.6 Sanofi S.A.
11.6.1 Sanofi S.A. Company Detail
11.6.2 Sanofi S.A. Business Overview
11.6.3 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.6.4 Sanofi S.A. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.6.5 Sanofi S.A. Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Detail
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.7.4 Novartis AG Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.7.5 Novartis AG Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Detail
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.8.4 Eli Lilly and Company Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.8.5 Eli Lilly and Company Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Detail
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.9.4 Merck & Co. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.9.5 Merck & Co. Recent Development
11.10 Viventia Bio Inc.
11.10.1 Viventia Bio Inc. Company Detail
11.10.2 Viventia Bio Inc. Business Overview
11.10.3 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.10.4 Viventia Bio Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.10.5 Viventia Bio Inc. Recent Development
11.11 Celgene Corporation
11.11.1 Celgene Corporation Company Detail
11.11.2 Celgene Corporation Business Overview
11.11.3 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.11.4 Celgene Corporation Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.11.5 Celgene Corporation Recent Development
11.12 Spectrum Pharmaceuticals, Inc.
11.12.1 Spectrum Pharmaceuticals, Inc. Company Detail
11.12.2 Spectrum Pharmaceuticals, Inc. Business Overview
11.12.3 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.12.4 Spectrum Pharmaceuticals, Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.12.5 Spectrum Pharmaceuticals, Inc. Recent Development
11.13 Herantis Pharma Plc.
11.13.1 Herantis Pharma Plc. Company Detail
11.13.2 Herantis Pharma Plc. Business Overview
11.13.3 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.13.4 Herantis Pharma Plc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.13.5 Herantis Pharma Plc. Recent Development
11.14 Taris Biomedical LLC
11.14.1 Taris Biomedical LLC Company Detail
11.14.2 Taris Biomedical LLC Business Overview
11.14.3 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.14.4 Taris Biomedical LLC Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.14.5 Taris Biomedical LLC Recent Development
11.15 Prometic Life Sciences Inc.
11.15.1 Prometic Life Sciences Inc. Company Detail
11.15.2 Prometic Life Sciences Inc. Business Overview
11.15.3 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.15.4 Prometic Life Sciences Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.15.5 Prometic Life Sciences Inc. Recent Development
11.16 Telormediz S.A.
11.16.1 Telormediz S.A. Company Detail
11.16.2 Telormediz S.A. Business Overview
11.16.3 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.16.4 Telormediz S.A. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.16.5 Telormediz S.A. Recent Development
11.17 Heat Biologics
11.17.1 Heat Biologics Company Detail
11.17.2 Heat Biologics Business Overview
11.17.3 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.17.4 Heat Biologics Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.17.5 Heat Biologics Recent Development
11.18 Altor BioScience
11.18.1 Altor BioScience Company Detail
11.18.2 Altor BioScience Business Overview
11.18.3 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.18.4 Altor BioScience Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.18.5 Altor BioScience Recent Development
11.19 Ferring B.V.
11.19.1 Ferring B.V. Company Detail
11.19.2 Ferring B.V. Business Overview
11.19.3 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.19.4 Ferring B.V. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.19.5 Ferring B.V. Recent Development
11.20 Cold Genesys Inc.
11.20.1 Cold Genesys Inc. Company Detail
11.20.2 Cold Genesys Inc. Business Overview
11.20.3 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.20.4 Cold Genesys Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.20.5 Cold Genesys Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details